IL6 and pancreatic ductal adenocarcinoma: High serum levels of IL-6 have been associated with poor overall survival prognosis in patients with highly malignant pancreatic cancer [46], and increased activity of IL-6/STAT3-mediated signaling has been reported to be associated with poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC) after resection [47].